(January 19, 2021, 1:52 PM EST) -- LOS ANGELES — A biotechnology company and its CEO violated federal securities law by misrepresenting to investors that the company had developed a rapid-result finger-prick blood test for the detection of COVID-19 even though it had not developed any viable test, an investor alleges in a securities class action lawsuit filed Jan. 15 in California federal court....